Johnson & Johnson (JNJ)
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstrating the defensive strength that has made JNJ a cornerstone holding for income-focused investors.
Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato
CNBC's Jim Cramer sits down with Johnson & Johnson CEO Joaquin Duato to talk about the company's outlook, President Trump's 100% tariff on some pharmaceutical imports, cancer treatment innovation and more.
Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDT Company Participants Tom Cavanaugh - Company Group Chairman for North America Innovative Medicine Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co., LLC.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
3 Dividend Stocks to Hold Through Market Volatility This Fall
Stocks are rallying on the expectation that the Federal Reserve will cut interest rates by 25 basis points in September. That should be positive for corporate earnings.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Okay. Are we ready to go.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
